8 results about "Endothelial dysfunction" patented technology

The application provides medical uses of knocking down or inhibiting a circular RNA circ0030586, in particular, applications of a substance for knocking out or knocking down circ0030586 or a substance for inhibiting expression of circ0030586 in (A1)-(A2) as follows: (A1) preparing a drug for treating or assisting in treating a cardiovascular disease caused by endothelial dysfunction; (A2) preparing a drug for preventing or assisting in preventing a cardiovascular disease caused by endothelial dysfunction. In patients with atherosclerosis caused by endothelial dysfunction and cell and animal models related to atherosclerosis, it is found that inhibiting circ0030586 can delay the progression of atherosclerosis; the application provides a new target for diagnosis and treatment of atherosclerosis related vascular diseases caused by aging, and opens up a new direction for preparation of prevention and treatment drugs.

This invention proposes compounds of formula IA, IB, IC, ID, IE, IF, IG, IH, or IJ for the treatment or prevention of the following vascular endothelial dysfunction or vascular leakage diseases:

The application belongs to the technical field of medicine, and particularly relates to a blood vessel targeting anti-aging oral composition and application thereof. In view of problems such as endothelial dysfunction, matrix sclerosis and accumulation of senescent cells caused by vascular aging, the composition comprises active ingredients: beetroot extract, fisetin, salvianolic acid B, panax notoginseng total saponins, cocoa flavanol, pterostilbene, procyanidin B2, luteolin, nicotinamide riboside and astaxanthin. The composition is prepared by a process of adsorbing astaxanthin on beetroot extract, mixing other active ingredients, fillers and glidants after fisetin and salvianolic acid B are prepared into a solid dispersion, and sequentially cooperating each module, so that the pulse wave transmission velocity can be significantly reduced and the skeletal muscle capillary density can be increased, and the composition is mainly used for preparing a medicine for improving vascular stiffness, promoting microcirculation and removing vascular senescent cells.

The application discloses an application of perirenal adipose tissue exosomes rich in miRNA-486 in inducing endothelial dysfunction, wherein the perirenal adipose tissue exosomes are derived from adipose tissue around mammalian kidneys, rich in micro miRNA-486, have a particle size of 30-150 nanometers, have surface markers CD63, CD81 and TSG101, and have an expression level of the miRNA-486 in the perirenal adipose tissue exosomes increased by 3-5 times relative to a normal control, so that the perirenal adipose tissue exosomes can transmit the miRNA-486 to cells when being taken by vascular endothelial cells, and induce abnormal functions of the endothelial cells. The application proves that the perirenal adipose tissue exosomes rich in miR-486 can be taken by vascular endothelial cells in a specific manner through in-vivo and in-vitro experiments.

A method for determining a risk of sepsis in a patient is disclosed. The method includes collecting an exhaled breath sample, determining a NO concentration in the exhaled breath sample; and determining a sepsis risk score correlated to the NO concentration, wherein the sepsis risk score is indicative of a risk of a patient having or developing sepsis. The method may further include determining an additional measurement of the patient's vital statistics including one or more of: end tidal CO2, respiratory rate, pulse rate, body temperature, cognitive assessment score, systolic blood pressure, diastolic blood pressure, or hemoglobin oxygen saturation level, and further determining the sepsis risk score based on the additional measurement.

This invention discloses the use of tanshinone or its pharmaceutically acceptable salts or derivatives in the preparation of PDK4 agonists. Tanshinone reverses EndMT and inhibits the progression of coronary artery disease atherosclerosis and endothelial dysfunction by restoring the metabolic regulator PDK4. It effectively prevents the progression of coronary artery disease by targeting anti-EndMT and metabolic regulation to improve abnormal endothelial function. The use of tanshinone in the preparation of drugs for treating angina pectoris in coronary artery disease opens up new application areas for tanshinone.

This invention provides a strain of Akkermansia myxophilus ( Akkermansia muciniphila The present invention provides a probiotic preparation comprising the aforementioned Akkermansia myxophilus or its post-genetically modified organism (PGA). The Akkermansia myxophilus or its post-genetically modified organism (PGA) of the present invention can improve vascular endothelial cell function, increase testosterone secretion, and thus improve erectile dysfunction and reproductive capacity. The probiotic preparation of the present invention may comprise the aforementioned Akkermansia myxophilus or its post-genetically modified organism (PGA) and yohimbine. This preparation can improve erectile dysfunction caused by vascular endothelial dysfunction, improve reproductive function in aged mice, and the components in this preparation have a synergistic effect.